💥 How Does Melatonin Stack Up Against New Cancer Drugs?

No oncologist is going to tell you this — and that’s telling.

  • Most newly approved cancer drugs by the FDA, Health Canada, or EMA show a 2%–12% improvement in 1-year survival. That’s often considered a success.

  • Now consider this: Melatonin — a naturally occurring hormone with virtually no severe side effects — showed a 34% reduction in 1-year mortality across solid tumors in meta-analyses. That’s not just good. That’s staggering in a good way!

  • Why this is important, even for Supportive care — Melatonin reduced common side effects such as fatigue, thrombocytopenia, nausea, and insomnia, especially in patients on corticosteroids or radiation

  • Melatonin is inexpensive, widely available, and has shown to be well-tolerated up to 1000 mg/day in clinical studies. Yet it’s ignored or dismissed in nearly all conventional oncology conversations.

Proposed Anti-Tumor Mechanisms of Melatonin

Cell Proliferation Inhibition

Modulates cell cycle proteins; reduces tumor cell proliferation and self-renewal.

Cyclins, cyclin-dependent kinases, CD133, SOX2

Apoptosis Induction

Increases pro-apoptotic mediators; decreases anti-apoptotic proteins.

BAX, BAK, Apaf-1, Caspases, p53, Bcl-2

Angiogenesis Inhibition

Suppresses growth factors and enzymes involved in new blood vessel formation.

VEGF, MMPs, HIF-1α

Immune System Modulation

Enhances activity of immune cells; modulates cytokine release.

NK cells, CTLs, Macrophages, IL-2, IL-6, TNF-α

Epigenetic Regulation

Alters DNA methylation patterns and histone modifications; downregulates oncogenes, upregulates tumor suppressors. ABCG2 promoter, Histone deacetylase, miR-24

Tumor Microenvironment Modulation

Reduces adhesion molecules; attenuates monocyte recruitment; influences mesenchymal stromal cells.

ICAM-1, VCAM-1, CCL2, SIRT1, NF-kB, MAP kinase, Vimentin, Collagen

Anti-Metastatic Effects

Modulates cell-cell/matrix interaction; remodels extracellular matrix; influences EMT.

ADAMTS family, MMP-9, MMP-13, Vimentin

Oxidative Stress Modulation

Paradoxical pro-oxidant effect in cancer cells; antioxidant in normal cells.

ROS, Mitochondrial DNA, Nrf2

Metabolic Reprogramming

Inhibits Warburg effect; reduces glucose metabolism.

Pyruvate dehydrogenase kinase (PDK)

Overcoming Chemoresistance

Downregulates drug efflux transporters.

ABCG2/BCRP

Here’s what the data actually shows:

  • Lissoni (1999): In a randomized study, 20 mg/day of melatonin with radiotherapy improved 1-year survival in GBM patients (43%) vs. radiotherapy alone (6%)

  • Lissoni et al. (2020): In a preliminary Phase 2 study, 1000 mg/day melatonin achieved disease stabilization in 54% of advanced cancer patients, including 2 out of 5 with glioblastoma

  • *Meta-analyses: Across solid tumors, melatonin use reduced 1-year mortality risk by ~34% — a remarkable figure when you consider that melatonin is a naturally occurring hormone with a strong safety profile, low cost, and virtually no severe side effects.

  • In oncology, even a 5–10% survival benefit can be considered meaningful.

  • A 34% reduction in death risk with something as accessible and well-tolerated as melatonin is not just clinically impressive — it's a signal that this compound deserves far more attention in serious cancer care. These studies also showed improved response rates and better tolerance to chemotherapy.


This isn’t theory.

It’s clarity that until now, no one’s offering.

We pulled the pieces together so you don’t have to.
👉 [Grab our Melatonin & GBM Guide]

Interactive Report: Melatonin & Glioblastoma

Melatonin as an Adjuvant Therapy in Glioblastoma

An interactive exploration of the scientific evidence, from preclinical promise to the reality of clinical data.

Executive Summary: The Core Finding

The central question for many patients and clinicians is whether high-dose melatonin (specifically 1000 mg/day or more) is a viable adjuvant treatment for Glioblastoma (GBM). Based on available clinical research, the answer is nuanced:

For Glioblastoma patients taking 1000 mg/day or more of melatonin **YES, a benefit was observed in a preliminary study.** In a Phase 2 study of untreatable advanced cancer patients (including 5 GBM and 1 Malignant Astrocytoma patient), where melatonin was often the only treatment:

  • Disease control (stable disease) was achieved in 54% of patients.
  • Responses lasted a median of 5 months, with some over 11 months.
This is significant for patients with limited options.

While melatonin shows significant anti-cancer promise in lab settings and is well-tolerated, dedicated large-scale GBM trials for this dose are still needed.

The Evidence Deep Dive

Explore the detailed evidence behind melatonin's potential role. Use the tabs below to switch between clinical trial data, the underlying science from lab studies, safety information, and official guidelines.

Standard Dose (20mg/day) in Brain Tumors: A Mixed Picture

The few clinical trials using a 20mg/day dose for brain tumors have yielded conflicting results, highlighting the need for more specific research in GBM.

Very High Dose (1000mg/day): The Only Study

A single preliminary Phase 2 study investigated this dose in a small group of untreatable advanced cancer patients, often as a mono-treatment when no other options were available. The cohort included 5 Glioblastoma patients and 1 Malignant Astrocytoma patient. Of these 6 brain tumor patients:

  • 3 Glioblastoma patients had Progressive Disease (PD).
  • 1 Glioblastoma patient achieved Stable Disease (SD) for 10+ months.
  • 1 Glioblastoma patient achieved Stable Disease (SD) for 5 months.
  • 1 Malignant Astrocytoma patient achieved Stable Disease (SD) for 11+ months.
This study reported disease control in 54% of the overall 13 patients, with a median response duration of 5 months (ranging from 3 to over 11 months). For patients facing a dire prognosis, even these modest extensions are highly significant, especially considering the context of a mono-treatment in untreatable cases.

How It Works (In the Lab)

In preclinical studies, melatonin fights cancer through many different pathways. Click on each mechanism below to learn more about how it targets cancer cells.

Safety Profile & Drug Interactions

General Tolerability

Melatonin is generally considered safe with mild, transient side effects. Even the 1000mg/day dose was reported as "well tolerated."

  • ●
    Common: Drowsiness, headache, dizziness, nausea.
  • ●
    Less Common: Vivid dreams, stomach cramps, irritability.

Critical: Drug Interactions

GBM patients are often on multiple medications. Melatonin can interact with them. This is a critical conversation to have with a doctor.

Potential interactions include:
  • Anticoagulants (blood thinners)
  • Anti-seizure medications
  • High blood pressure medications
  • Immunosuppressants
  • Diabetes medications
  • Corticosteroids (e.g., Dexamethasone)

This interactive report is for informational purposes only and does not constitute medical advice. Consult with a qualified healthcare professional for any health concerns or before making any treatment decisions.

Data synthesized from "A Preliminary Phase-2 Study with very High-Dose of Melatonin (1000 mg/day) in Untreatable Advanced Cancer Patients Already Progression on Previous Palliative Therapy with High-Dose Melatonin."

CALMOVERCANCER.COM | ALL RIGHTS RESERVED - TERMS & CONDITIONS